The global genomics market size was valued at USD 28.09 billion in 2022 and is projected to witness a compound annual growth rate (CAGR) of 16.5% from 2023 to 2030. The growth of genomics market is attributed to factors such as the growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed into a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.
The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19. For example, the viral genome mutational rate (~1-2 bases per month) was gauged for the validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.
Many genomic surveillance programs were launched country wise to understand the dynamics of the pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.
The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).
Implementation of Artificial Intelligence (AI) in genomics is gaining popularity from past few years. Artificial intelligence algorithms are used to analyze genomic data generated through sequencing technologies, enabling faster and more accurate identification of genetic variations that are responsible for a disease. Furthermore, artificial intelligence is used to analyze genetic data and develop personalized treatment plans for patients. This approach takes into account an individual's genetic makeup and can help doctors prescribe the most effective treatment for a particular patient.
The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.
The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.
The functional genomics segment dominated the overall market with the largest revenue share of 37.1% in 2022. The dominance of the segment can be attributed to research studies aiming to understand a particular phenotypical expression of a given disease condition. Many gene therapies for cancers are designed on the basis of functional genomic technology. For instance, in June 2020, researchers at European Molecular Biology Laboratory (EMBL) at Heidelberg increased the scalability and precision metrics of functional genomics CRISPR/Cas9 gene-based screens through targeted single-cell RNA sequencing. Single-cell RNA sequencing gives deep insights into levels of gene expression in individual cells and can capably analyze CRISPR/Cas9 functional genomics screens.
Pathway analysis segment is predicted to emerge as the most lucrative of all by 2030. The segment is likely to grow at a CAGR of 17.1% from 2023 to 2030. Usage of pathway analysis in developing next-generation therapeutics has emerged one of the most growing applications. Pathway-based analysis has gained more attention after the emergence of clinical genomics and personalized therapies. This is mainly because genomics and personalized therapies aid in the in-depth analysis of the ability to navigate signaling pathways and disease networks.
The product segment dominated the market and accounted for a revenue share of 69.7% of the market in 2022. The products used in genomics are broadly segmented into two categories—instruments or systems that are required for the synthesis and sequencing of the nucleic acid sequences and consumables & reagents.
The increase in preference for personalized medicines and decline in costs of DNA sequencing owing to the launch of NGS technology resulted in the development of novel products or systems. The genomics market is gradually becoming more competitive with new product launches. For instance, in June 2022, PerkinElmer introduced an automated benchtop system for NGS, the research-use only BioQule NGS System to automate library preparation.
The service segment is expected to register a steady CAGR by 2030. The high cost of products, the demand for expertise required for genomics, and the focus on core operations by the end user are the major factors driving the services segment. NGS-based services held a major share in the genomics services segment due to the rapid adoption of Whole Genome Sequencing (WGS) and applications of sequence databases for disorder screening and prognosis. However, data processing and interpretation, rather than data production has become the need for current development and application.
The pharmaceutical and biotechnology companies segment led the market and accounted for a revenue share of 49.4% in 2022. This is attributed to the increasing demand for use of genomics in drug discovery. Moreover, the market is driven by increasing adoption of spatial genomics & transcriptomics technologies. Numerous trials are underway for novel drug discovery using underlying knowledge from genomics. For instance, in June 2022, Illumina Inc., declares that it will present seven of their abstracts regarding the key oncology research at the American Society of Clinical Oncology (ASCO) 2022 in further to an event to discuss the transformational impact of comprehensive genomic profiling in precision medicine.
The hospital and clinic segment is estimated to grow at a substantial pace during the forecast period. Several hospitals and clinics are currently offering genomic sequencing services to patients and are using this technology in the daily practice of medicine. Stanford Medicine is one such facility that provides genomic sequencing services to patients with a rare or unidentified condition that is thought to be genetic. The first hospital system to offer the general public services for genetic sequencing, analysis, and interpretation is Partners HealthCare based in the U.S. It has enrolled over 200 patients and physicians in a study funded by NIH to study the integration of whole genome sequencing in clinical medicine.
North America accounted for the largest market share of 42.57% in 2022. This is attributed to the support of research institutes and pharmaceutical giants. Genomics is now an integral part of any disease research and drug discovery due to the implications of genetic expression on human health. There are emerging advancements in the region for the utility of genomics with collaborative efforts. For instance, in January 2022, Illumina, Inc. collaborated with Nashville Biosciences, LLC, (part of Vanderbilt University Medical Center at Tennesee), for drug development by using genomics and to establish a preeminent clinico-genomic resource.
Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to increased demand for genomics applications in diagnostics and the growing demand for novel therapeutic drugs to fight the increased incidence of diseases in the region. Several major human genome sequencing projects are being performed, one of the most recent projects is Genome Asia 100K. Under this project, 100,000 Asian genomes would be sequenced and analyzed, which can help accelerate population-specific medical advances and precision medicine. With this project, GA 100K was expected to identify new possible therapeutic drugs and understand the biology of diseases.
Key players operating in the market are focused on strategic collaborations, new product launches, and geographical expansions where needed in emerging and favorable regions across the globe. For instance, in February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region. Some of the prominent companies in the global genomics market include:
Bio-Rad Laboratories, Inc.
Color Genomics, Inc.
F. Hoffmann-La Roche Ltd.
Myriad Genetics, Inc.
Oxford Nanopore Technologies
Pacific Biosciences of California, Inc.
Quest Diagnostics Incorporated
Thermo Fisher Scientific, Inc.
In June 2023, BGI Genomics was recognized as the GB/T 35770-2022/ISO 37301 Compliance Management System accreditation-approved company, after the extensive evaluation of BSI, a global testing, standardization, and certification authority. This indicates that BGI Genomics complies with international standards for high-quality and reliable product development.
In June 2023, Myriad Genetics and The University of Texas MD Anderson Cancer Center announced their collaboration aimed at metastatic renal cell carcinoma treatment selection and response research and incorporating Myriad’s minimal residual disease testing platform based on whole genome sequencing.
At the June 2023 annual meeting held by the American Society of Clinical Oncology (ASCO), Myriad Genetics highlighted advancements in its oncology footprint, such as the inclusion of the Folate Receptor Alpha (FRα) biomarker in its Precise™ Oncology Solutions portfolio and hiring experts to its oncology leadership team.
In June 2023, BGI Genomics unveiled Genalive, a self-regulating clinical laboratory; a collaborative venture between Tibbiyah Holding and BGI Almanahil Health for Medical Services, a subsidiary of BGI Genomics in Saudi Arabia. Genalive will offer precision medicine solutions and comprehensive genetic testing with its cutting-edge sequencing platforms, AI-driven analytical tools, and advanced bioinformatics pipelines. This is marked as BGI Genomics’ milestone in its global expansion of genetics research.
In April 2023, Bio-Rad Laboratories, Inc. pivoted their measurable residual disease (MRD) genomics research via a half dozen collaborations with companies and institutions to launch their new QX600™ Droplet Digital™ PCR System. It has gained FDA clearance and claims to deliver a simple user workflow, six color detection capabilities for measuring 12 targets per well, and powerful data analysis.
In April 2023, the New York State (NYS) Department of Health Clinical Laboratory Evaluation Program certified Intermountain Precision Genomics and Myriad Genetics to offer solid tumor testing solutions to patients across all 50 states. Intermountain Precision Genomics offers Myriad’s Precise™ Tumor test as TheraMap® to analyze tumor DNA to identify cancer-causing gene mutations.
In July 2021, SOPHiA GENETICS and GE Healthcare entered into a partnership to advance cancer care by matching patients’ genomic profiles and offers personalized treatment. The collaboration was intended to develop AI-powered workflow solutions and analytics, serving both biopharma and clinical markets.
Market size value in 2023
USD 32.64 billion
Revenue forecast in 2030
USD 94.86 billion
CAGR of 16.5% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Application & technology, deliverables, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Agilent Technologies; Bio-Rad Laboratories, Inc.; BGI Genomics; Color Genomics, Inc.; Danaher Corporation; Eppendorf AG; Eurofins Scientific; F. Hoffmann-La Roche Ltd.; GE Healthcare; Illumina, Inc.; Myriad Genetics, Inc.; Oxford Nanopore Technologies; Pacific Biosciences of California, Inc.; QIAGEN N.V.; Quest Diagnostics Incorporated; Thermo Fisher Scientific, Inc.; 23andMe, Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the genomics market based on application & technology, deliverables, end-use, and region:
Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)
Chromatin Immunoprecipitation (ChIP & ChIP-Seq)
Methylated DNA Immunoprecipitation (MeDIP)
High-Resolution Melt (HRM)
Chromatin Accessibility Assays
Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)
Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)
Consumables & Reagents
Core Genomics Services
Biomarker Translation Services
End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Academic & Government Institutes
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other End Users
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
Middle East & Africa
b. The global genomics market size was estimated at USD 28.09 billion in 2022 and is expected to reach USD 32.64 billion in 2023.
b. The global genomics market is expected to witness a compound annual growth rate of 16.5% from 2023 to 2030 to reach USD 94.86 billion by 2030.
b. The pharmaceutical and biotechnology companies segment accounted for the major revenue share owing to the increasing number of genetic research studies aimed at the development of efficacious drugs with fewer side effects and improving the drug discovery process.
b. Major players in the genomics market include F. Hoffmann-La Roche Ltd..; Agilent Technologies, Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; 23andMe, Inc.; Illumina, Inc.; Myriad Genetics, Inc.; Foundation Medicine, Inc.; Danaher, Pacific Biosciences; Oxford Nanopore Technologies; and BGI.
b. Technological advancements in genetic tools, as well as molecular diagnostics, is one of the key driving force that has accelerated investment by genomic companies in the market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for COVID-19. The report will account for COVID-19 as a key market contributor.